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Insulin Neuritis: an old, but still an unfamiliar and mysterious condition 
 
Authors: 
Yun Tae Hwang1, Gerard Davies1 
 
1. Department of Neurology, Royal Free Hospital, United Kingdom 
 
 
Corresponding author: 
Yun Tae Hwang 
Department of Neurology 
Royal Free Hospital 
London NW3 2QG 
United Kingdom 
Phone no: +44 207 794 0500 
E-mail: yun.hwang@nhs.net 
 
 
Keywords: insulin neuritis, acute small fibre neuropathy, diabetic neuropathy, autonomic 
neuropathy 
Word Count:  
  
Abstract 
Insulin neuritis is a historical term for an acute neuropathy affecting diabetic patients who achieve 
rapid re-establishment of previously poor glycaemic control. It presents with neuropathic pain, 
symptoms of autonomic dysfunction, or a combination of both. Recently it has been proposed that 
‘treatment induced neuropathy of diabetes’ would be a more accurate name for this entity. The 
management focuses on controlling the symptoms while they gradually improve with time.  
 
 
  
INTRODUCTION 
Diabetes mellitus is a common cause of small fibre neuropathy. It typically presents with sensory 
alterations and neuropathic pain in a ‘glove-and-stocking’ distribution, beginning insidiously after 
many years of impaired glycaemic control. The symptoms of autonomic system involvement may 
also accompany neuropathic pain.  
 
Rarely, however, diabetic patients can present with an acute onset of small fibre neuropathy with 
prominent autonomic features, neuropathic pain, or both, in association with the re-establishment 
of good glycaemic control. Often, these patients are referred to the neurologist’s attention with a 
concern about a rapidly progressive neurological illness with prominent autonomic features after 
they present to the emergency department with postural hypotension and a rapidly evolving 
neuropathy. Usually, these patients have excellent glycaemic control and they are not necessarily 
flagged to the local endocrinology service before the neurology review is requested.   
 
We present two cases that illustrate the range of presentations of the acute treatment induced 
small fibre neuropathy in diabetic patients, or ‘insulin neuritis’. 
 
CASE 1 
A 22 year old woman presented to the emergency department after passing out in a shopping 
centre. She described multiple episodes of syncope in the preceding month, along with palpitations, 
reduced appetite without nausea and vomiting and painful pins and needles up to just above the 
ankles  She denied bowel and bladder dysfunction. Her past history was significant for type 1 
diabetes mellitus diagnosed at the age of 6 years, reduced vision in her left eye due to corneal 
abrasions from a traumatic injury and a recent diagnosis of non-alcoholic steatohepatitis (NASH) 
attributed to poorly controlled diabetes, which prompted her to become more diligent about 
maintaining glycaemic control. There was no history of eating disorder or a mental illness. 
 Physical examination revealed blood pressure of 128/73 mmHg on lying and 90/62 mmHg on 
standing and sinus tachycardia of between 110 and 120 and beats per minute.  The neurological 
examination revealed normal tone and power with symmetrically brisk reflexes and altered 
sensation up to just above the ankles to light touch and pinprick. Proprioception was preserved. 
There were no cerebellar signs. The rest of the general examination was normal.  
 
Her glycated haemoglobin (HbA1c) results were 101.1 mmol/mol (11.4%) 12 months prior to the 
presentation; it had dropped to 92.4 mmol/mol (10.6%) 4 months prior to admission and on 
admission was 80.3 mmmol/mol (9.5%).  Nerve conduction studies revealed a generalised axonal 
neuropathy affecting large fibres with autonomic involvement  . 
 
During the admission, her postural hypotension improved with increased fluid intake and she was 
commenced on gabapentin 300mg TDS for neuropathic pain. Other autonomic symptoms were mild 
and did not require specific therapy. She was discharged after 4 days in hospital to be followed up in 
the community by the local diabetes and the neurology service and her symptoms were persistent 
but milder at 4 weeks after discharge.  
 
CASE 2 
A 24 year old woman presented to the emergency department with syncope shortly after 
complaining of chest pain and palpitations, two weeks after she was a passenger in a minor motor 
vehicle accident. Her past history was significant for type 1 diabetes diagnosed at 8 years of age, 
although she had been lost to follow up for several years until 1 month prior to this presentation. 
There was no other medical or psychiatric history. She was hypotensive (98/62 mmHg lying) with a 
further drop on sitting up (74/46 mmHg) and tachycardic at 130 to 150 beats per minute. Aortic 
dissection and pulmonary embolism was ruled out in the emergency department and she was 
admitted to the ward for cardiac monitoring. On the ward, she poorly tolerated sitting up with a 
highly variable heart rate between 70 beats per minute to 120 beats per minute. She also described 
a 2 week history of neuropathic pain in her feet, persistent nausea and vomiting after meals, 
irregular bowel movements and persistent but non-specific lower abdominal discomfort. 
Subsequent investigations confirmed gastroparesis and urinary retention as suggested by the 
history.  
 
Her HbA1c was not checked as it was deemed ‘too soon’ from the previous HbA1c check of 12.2% 
(109.8 mmol/mol and suggesting average blood sugar of 16.8 mmol/l) 3 weeks ago but her serum 
blood sugar readings prior to the admission according to her logbook were between 5 mmol/l and 
12 mmol/l, consistent with significantly improved glycaemic control. 
 
She was commenced in ivabradine 5mg BD for tachycardia, domperidone 10 mg TDS and 
erythromycin 500 mg TDS for gastroparesis, fludrocortisone 150 micrograms daily for postural 
hypotension and pregabalin 150 mg BD for neuropathic pain. These symptoms gradually improved 
during a prolonged hospital stay. At 9 months post discharge, she had completely recovered with no 
symptoms off all medications with excellent glycaemic control. 
 
DISCUSSION 
Acute small fibre neuropathy related to an improvement in glycaemic control in diabetic patients 
was first described in 1933 by Caravati,[1] only 11 years after Banting and MacLeod first 
administered bovine insulin to humans. He called it ‘insulin neuritis’, although this is a slight 
misnomer as insulin is not thought to be directly implicated in the pathogenesis of this condition, 
and there are several cases beginning after the patients commenced oral hypoglycaemic agents or 
achieving glycaemic control purely with weight loss.[2,3] The common denominator in all the 
reported cases are clear improvements in glycaemic control preceding the onset of the symptoms, 
and the term ‘treatment induced neuropathy of diabetes’, as proposed by Gibbons and Freeman,[2] 
may be a more appropriate term.  
 
Two different pathological findings have been reported in these patients. Tesfaye et al found a 
proliferation of epineural vessels with evidence of arterio-venous shunting on sural nerve 
photography of five patients affected with this condition.[4] They proposed that the resulting 
vascular ‘steal’ effect leads to ischaemia of endoneurium and neuropathic pain.  On the other hand 
Llewelyn et al reported a sural nerve biopsy of a single patient with insulin neuritis and found 
histopathological evidence of chronic neuropathy with prominent regeneration activity.[5] They did 
not find any evidence of vasa nervorum abnormalities and proposed that the normoglycaemic state 
promotes the regeneration of damaged axons which results in ectopic signal generation and 
neuropathic pain. While the latter theory is more consistent with the current understanding of 
neuropathic pain, neither of these findings has been replicated. The precise pathophysiology and the 
reasons for the development of clinical syndrome remain unclear.  
 
Overall, insulin neuritis is a rare condition with no data on its prevalence or incidence and most of 
the literature since its initial description consists of only a handful of patients. The exception is the 
recent paper by Gibbons and Freeman that included 104 patients with insulin neuritis encountered 
over five years at a tertiary neurology centre in the United States.[6] This series confirmed that the 
symptoms of insulin neuritis improve over time, consistent with the past reports and our experience. 
While waiting for the symptoms to improve, symptomatic treatments, in consultation with other 
relevant specialties, should be offered to the patient. It is unclear at this stage whether relaxation of 
glycaemic control is warranted and whether this would lead to a more rapid resolution of insulin 
neuritis but the current consensus is that the good glycaemic control should not be relaxed. If that 
were to be shown, any consideration of this would need to be weighed against the long term 
benefits of establishing good glycaemic control quickly.   
 It is likely that insulin neuritis will become more common as the overall prevalence of diabetes 
increases and as better treatments allow for tighter glycaemic control. From the clinical perspective, 
it is an important condition to recognise so that the diagnosis can be made rapidly, the symptoms 
treated, and the patients reassured that overall the prognosis is relatively benign.    
 
KEY POINTS 
 Insulin neuritis, or treatment induced neuropathy of diabetes, is seen in diabetic patients 
who achieve rapid re-establishment of previously poor glycaemic control 
 Insulin neuritis Treatment induced neuropathy of diabetes can present with neuropathic 
pain, symptoms of autonomic dysfunction, or a combination of both.  
 Treatment consists of symptom management, in conjunction with other specialties.  
 Overall prognosis is benign, with complete recovery expected. 
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